S&P Futures
4,070.25 -5.25 (-0.13%) Dow Futures
34,442.00 -17.00 (-0.05%) Nasdaq Futures
11,993.25 -17.00 (-0.14%) Russell 2000 Futures
1,893.30 -1.10 (-0.06%) Crude Oil
81.39 +1.41 (+1.76%) Gold
1,820.30 +10.70 (+0.59%)
AgeX Therapeutics, Inc. (AGE)
After hours:
- Business Wire
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
ALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio
- Business Wire
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
ALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022.
- Business Wire
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.
